ANIK
Price
$14.72
Change
-$0.00 (-0.00%)
Updated
Jun 12 closing price
Capitalization
195.86M
52 days until earnings call
Intraday BUY SELL Signals
RDY
Price
$13.30
Change
-$0.06 (-0.45%)
Updated
Jun 12 closing price
Capitalization
11.08B
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIK vs RDY

Header iconANIK vs RDY Comparison
Open Charts ANIK vs RDYBanner chart's image
ANIK vs RDY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANIK vs. RDY commentary
Jun 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Buy and RDY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2026
Stock price -- (ANIK: $14.72 vs. RDY: $13.30)
Brand notoriety: ANIK and RDY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIK: 53% vs. RDY: 49%
Market capitalization -- ANIK: $195.86M vs. RDY: $11.08B
ANIK [@Pharmaceuticals: Generic] is valued at $195.86M. RDY’s [@Pharmaceuticals: Generic] market capitalization is $11.08B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 2 green FA rating(s).

  • ANIK’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 2 green, 3 red.
According to our system of comparison, RDY is a better buy in the long-term than ANIK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 6 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).

  • ANIK’s TA Score: 6 bullish, 3 bearish.
  • RDY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ANIK is a better buy in the short-term than RDY.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а +1.66% price change this week, while RDY (@Pharmaceuticals: Generic) price change was +0.45% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.56%. For the same industry, the average monthly price growth was +23.25%, and the average quarterly price growth was +9.77%.

Reported Earning Dates

ANIK is expected to report earnings on Aug 05, 2026.

RDY is expected to report earnings on Jul 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.56% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($11.1B) has a higher market cap than ANIK($196M). RDY has higher P/E ratio than ANIK: RDY (24.74) vs ANIK (10.71). ANIK YTD gains are higher at: 53.174 vs. RDY (-5.271). RDY has higher annual earnings (EBITDA): 79.2B vs. ANIK (-6.71M). RDY has more cash in the bank: 87.8B vs. ANIK (41M). ANIK has less debt than RDY: ANIK (25.7M) vs RDY (77.3B). RDY has higher revenues than ANIK: RDY (336B) vs ANIK (116M).
ANIKRDYANIK / RDY
Capitalization196M11.1B2%
EBITDA-6.71M79.2B-0%
Gain YTD53.174-5.271-1,009%
P/E Ratio10.7124.7443%
Revenue116M336B0%
Total Cash41M87.8B0%
Total Debt25.7M77.3B0%
FUNDAMENTALS RATINGS
ANIK vs RDY: Fundamental Ratings
ANIK
RDY
OUTLOOK RATING
1..100
8723
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9565
PRICE GROWTH RATING
1..100
4459
P/E GROWTH RATING
1..100
10032
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (18) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ANIK (78) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than ANIK’s over the last 12 months.

RDY's Profit vs Risk Rating (89) in the Pharmaceuticals Generic industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to ANIK’s over the last 12 months.

RDY's SMR Rating (65) in the Pharmaceuticals Generic industry is in the same range as ANIK (95) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to ANIK’s over the last 12 months.

ANIK's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as RDY (59) in the Pharmaceuticals Generic industry. This means that ANIK’s stock grew similarly to RDY’s over the last 12 months.

RDY's P/E Growth Rating (32) in the Pharmaceuticals Generic industry is significantly better than the same rating for ANIK (100) in the Pharmaceuticals Other industry. This means that RDY’s stock grew significantly faster than ANIK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKRDY
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
48%
Momentum
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
49%
MACD
ODDS (%)
Bullish Trend 3 days ago
64%
Bearish Trend 3 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
46%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
41%
Advances
ODDS (%)
Bullish Trend 11 days ago
63%
Bullish Trend 20 days ago
47%
Declines
ODDS (%)
Bearish Trend 24 days ago
67%
Bearish Trend 12 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
63%
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANIK
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOON1.120.04
+3.70%
Kartoon Studios
PNR73.801.23
+1.69%
Pentair plc
MNR13.260.16
+1.22%
Mach Natural Resources LP
FSTR42.370.25
+0.59%
L.B. Foster Company
TCBIO20.410.03
+0.15%
Texas Capital Bancshares

ANIK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIK
1D Price
Change %
ANIK100%
N/A
RVTY - ANIK
39%
Loosely correlated
-1.83%
ORGO - ANIK
36%
Loosely correlated
-1.68%
AVNS - ANIK
35%
Loosely correlated
-0.08%
ACRS - ANIK
34%
Loosely correlated
-1.14%
FLGT - ANIK
32%
Poorly correlated
-0.53%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and HROW have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
-0.45%
HROW - RDY
28%
Poorly correlated
-0.03%
HLN - RDY
27%
Poorly correlated
+1.11%
TAK - RDY
27%
Poorly correlated
+0.25%
ZTS - RDY
26%
Poorly correlated
-2.25%
ANIK - RDY
25%
Poorly correlated
N/A
More